Global Healthcare Analyst

Tina Banerjee

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/lotus-pharmaceutical-co-ltd" target="_blank" data-smartkarma-citation="entities:20568:1" rel="noopener">Lotus Pharmaceutical (1795 TT)</a> achieved 10% revenue growth to NT$19B in 2024, while net profit increased 23% to NT$5B. Growth was mainly driven by the strong performance of export business.</li>
<li>For the first two months of 2025, the company reported revenue of NT$3B, representing 3% YoY growth. Particularly, January sales marked 9% YoY and a significant 48% MoM growth.</li>
<li>New launches and geography expansion of existing drugs will drive near-term growth. Lotus expects to launch 11 products in 2025. Valuation remains attractive and long-term growth story is still intact.</li>
</ul>



Lotus Pharmaceutical (1795 TT) achieved 10% revenue growth to NT$19B in 2024, while net profit increased 23% to NT$5B. Growth was mainly driven by the strong performance of export business.
For the first two months of 2025, the company reported revenue of NT$3B, representing 3% YoY growth. Particularly, January sales marked 9% YoY and a significant 48% MoM growth.
New launches and geography expansion of existing drugs will drive near-term growth. Lotus expects to launch 11 products in 2025. Valuation remains attractive and long-term growth story is still intact.


Lotus Pharmaceutical (1795 TT): Six Consecutive Years of Double-Digit Growth; Momentum to Continue

<ul>
<li>
<a href="https://www.smartkarma.com/entities/lotus-pharmaceutical-co-ltd" target="_blank" data-smartkarma-citation="entities:20568:1" rel="noopener">Lotus Pharmaceutical (1795 TT)</a> achieved 16% revenue growth to NT$17B in 2023, while net profit increased 36% to NT$4B. Growth was mainly driven by the strong performance of Asian business.</li>
<li>For the first two months of 2024, the company reported revenue of NT$3B, representing 1% YoY decline. While exports grew, Asia business remained flat. </li>
<li>1Q24 should be flat or slightly negative for the company, while growth is expected to pick up from the later half of the year.</li>
</ul>



Lotus Pharmaceutical (1795 TT) achieved 16% revenue growth to NT$17B in 2023, while net profit increased 36% to NT$4B. Growth was mainly driven by the strong performance of Asian business.
For the first two months of 2024, the company reported revenue of NT$3B, representing 1% YoY decline. While exports grew, Asia business remained flat. 
1Q24 should be flat or slightly negative for the company, while growth is expected to pick up from the later half of the year.


Lotus Pharmaceutical (1795 TT): Record-High Performance in 2023; What Lies Ahead?

Taiwan

TTY Biopharm Co., Ltd. manufactures and markets various kinds of medicines. The company's products encompass a variety of therapeutic segments, including cardiology, gastroenterology, orthopedics and cancer.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Tty Biopharm (4105 TT)

Lotus Pharmaceutical (1795 TT): Six Consecutive Years of Double-Digit Growth; Momentum to Continue

Lotus Pharmaceutical sees record high revenue, gross profit margin, and profit in 2024, driven by export business. The company should witness...

Tina Banerjee

Lotus Pharmaceutical (1795 TT): Record-High Performance in 2023; What Lies Ahead?

Lotus achieved 16% and 36%, YoY, revenue and profit growth, respectively, in 2023. The company is facing slight revenue decline in early 2024,...

Tina Banerjee

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Lotus Pharmaceutical (1795 TT): Six Consecutive Years of Double-Digit Growth; Momentum to Continue

​Lotus Pharmaceutical sees record high revenue, gross profit margin, and profit in 2024, driven by export business. The company should witness...

Tina Banerjee

Lotus Pharmaceutical (1795 TT): Record-High Performance in 2023; What Lies Ahead?

​Lotus achieved 16% and 36%, YoY, revenue and profit growth, respectively, in 2023. The company is facing slight revenue decline in early 2024,...

Tina Banerjee

Lotus Pharmaceutical sees record high revenue, gross profit margin, and profit in 2024, driven by export business. The company should witness...

Lotus achieved 16% and 36%, YoY, revenue and profit growth, respectively, in 2023. The company is facing slight revenue decline in early 2024,...